Cargando…

Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level

Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but complete remission rate is approximately 0%. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meng-Ke, Liu, Feng, Dai, Yu-Ting, Weng, Xiang-Qin, Cheng, Li-Li, Fan, Li-Quan, Liu, Han, Jiang, Lu, Sun, Xiao-Jian, Fang, Hai, Wang, Li, Zhao, Wei-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449247/
https://www.ncbi.nlm.nih.gov/pubmed/37638009
http://dx.doi.org/10.3389/fimmu.2023.1210909
_version_ 1785094913799487488
author Liu, Meng-Ke
Liu, Feng
Dai, Yu-Ting
Weng, Xiang-Qin
Cheng, Li-Li
Fan, Li-Quan
Liu, Han
Jiang, Lu
Sun, Xiao-Jian
Fang, Hai
Wang, Li
Zhao, Wei-Li
author_facet Liu, Meng-Ke
Liu, Feng
Dai, Yu-Ting
Weng, Xiang-Qin
Cheng, Li-Li
Fan, Li-Quan
Liu, Han
Jiang, Lu
Sun, Xiao-Jian
Fang, Hai
Wang, Li
Zhao, Wei-Li
author_sort Liu, Meng-Ke
collection PubMed
description Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but complete remission rate is approximately 0%. Therefore, the potential mechanisms of midostaurin resistance and the exact impacts of midostaurin on both gene expression profile and mast cell leukemia microenvironment in vivo are essential for design tailored combination therapy targeting both the tumor cells and the tumor microenvironment. Here we report a 59-year-old male mast cell leukemia patient with KIT F522C mutation treated with midostaurin. Single-cell sequencing of peripheral blood and whole exome sequencing (WES) of bone marrow were performed before and 10 months after midostaurin treatment. In accordance with the clinical response, compared to the pretreatment aberration, the decline of mast cells and increase of T-, NK, B-cells in peripheral blood, and the decrease of the KIT F522C mutation burden in bone marrow were observed. Meanwhile, the emergence of RUNX1 mutation, upregulations of genes expression (RPS27A, RPS6, UBA52, RACK1) on tumor cells, and increased frequencies of T and NK cells with TIGIT, CTLA4, and LAG3 expression were observed after midostaurin treatment, predicting the disease progression of this patient. As far as we know, this is the first case reporting the clinical, immunological, and molecular changes in mast cell leukemia patients before and after midostaurin treatment, illustrating the in vivo mechanisms of midostaurin resistance in mast cell leukemia, providing important clues to develop a sequential option to circumvent tumor progression after targeting oncogene addiction and prolong patients’ survival.
format Online
Article
Text
id pubmed-10449247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104492472023-08-25 Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level Liu, Meng-Ke Liu, Feng Dai, Yu-Ting Weng, Xiang-Qin Cheng, Li-Li Fan, Li-Quan Liu, Han Jiang, Lu Sun, Xiao-Jian Fang, Hai Wang, Li Zhao, Wei-Li Front Immunol Immunology Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but complete remission rate is approximately 0%. Therefore, the potential mechanisms of midostaurin resistance and the exact impacts of midostaurin on both gene expression profile and mast cell leukemia microenvironment in vivo are essential for design tailored combination therapy targeting both the tumor cells and the tumor microenvironment. Here we report a 59-year-old male mast cell leukemia patient with KIT F522C mutation treated with midostaurin. Single-cell sequencing of peripheral blood and whole exome sequencing (WES) of bone marrow were performed before and 10 months after midostaurin treatment. In accordance with the clinical response, compared to the pretreatment aberration, the decline of mast cells and increase of T-, NK, B-cells in peripheral blood, and the decrease of the KIT F522C mutation burden in bone marrow were observed. Meanwhile, the emergence of RUNX1 mutation, upregulations of genes expression (RPS27A, RPS6, UBA52, RACK1) on tumor cells, and increased frequencies of T and NK cells with TIGIT, CTLA4, and LAG3 expression were observed after midostaurin treatment, predicting the disease progression of this patient. As far as we know, this is the first case reporting the clinical, immunological, and molecular changes in mast cell leukemia patients before and after midostaurin treatment, illustrating the in vivo mechanisms of midostaurin resistance in mast cell leukemia, providing important clues to develop a sequential option to circumvent tumor progression after targeting oncogene addiction and prolong patients’ survival. Frontiers Media S.A. 2023-08-10 /pmc/articles/PMC10449247/ /pubmed/37638009 http://dx.doi.org/10.3389/fimmu.2023.1210909 Text en Copyright © 2023 Liu, Liu, Dai, Weng, Cheng, Fan, Liu, Jiang, Sun, Fang, Wang and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Meng-Ke
Liu, Feng
Dai, Yu-Ting
Weng, Xiang-Qin
Cheng, Li-Li
Fan, Li-Quan
Liu, Han
Jiang, Lu
Sun, Xiao-Jian
Fang, Hai
Wang, Li
Zhao, Wei-Li
Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
title Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
title_full Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
title_fullStr Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
title_full_unstemmed Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
title_short Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
title_sort case report: molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449247/
https://www.ncbi.nlm.nih.gov/pubmed/37638009
http://dx.doi.org/10.3389/fimmu.2023.1210909
work_keys_str_mv AT liumengke casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT liufeng casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT daiyuting casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT wengxiangqin casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT chenglili casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT fanliquan casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT liuhan casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT jianglu casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT sunxiaojian casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT fanghai casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT wangli casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel
AT zhaoweili casereportmolecularandmicroenvironmentchangeuponmidostaurintreatmentinmastcellleukemiaatsinglecelllevel